Decorative banner featuring photo of people standing on stairs

;

Reflections on King's Spinout Accelerator

13 February 2025

Academics and researchers across King's are advancing new ideas and innovations to address real-world challenges and create meaningful change. The King’s Spinout Accelerator offers a unique pathway to fast-track these groundbreaking solutions, but what’s the experience like for those on the programme? What have they valued most? Three spinouts share their insights.

PoMEGRANATE™

PoMEGRANATE™ are empowering women and couples to make healthy choices, leading to optimised pregnancy preparation, successful pregnancies and healthy babies.

Participating in the King’s Spinout Accelerator has been a transformative experience for our venture. The mentorship and resources available to us have been invaluable in refining the development of our technology and in establishing our business model and commercialisation strategy. The workshops and 1:1 guidance allowed us to tackle challenges and consider issues outside our comfort zone, with better clarity and confidence. We’re sure this programme will accelerate our path to market and highly recommend it to any spinout looking to take their innovation to the next level!” – PoMEGRANATE™ team

Academic leads: Dr Sara White and Dr Angela Flynn, Faculty of Life Sciences & Medicine.

Pharos AI

Pharos AI is a platform designed to navigate the path to AI-assisted healthcare within the NHS, to significantly accelerate the UK’s vision to deliver the right treatment, at the right time, for all patients, regardless of their socioeconomic background.

The accelerator was particularly useful to researchers and academics like me who believe commercialising their research would be of great benefit to society."– Dr Gregory Verghese

Academic leads: Professor Anita Grigoriadis and Dr Gregory Verghese, Faculty of Life Sciences & Medicine.

Prosemble

Prosemble are revolutionising drug delivery through the development of a novel nanocage platform, with chemically controlled assembly and disassembly. Targeted drug delivery is one of the biggest challenges in modern medicine, this technology aims to increase the efficacy of existing drugs and reduce their side effects.

We entered the accelerator with a vision, but emerged with a refined strategy and a deeper understanding of the complexities involved in the biotech landscape. One of the most valuable aspects of the accelerator was the knowledge we gained on how to approach big pharma with confidence. These insights have opened doors that we never thought possible, allowing us to gain crucial perspectives for our growth."– The Prosemble group

"The programme emphasised the importance of collaboration, and we learned how to effectively communicate our value proposition to potential partners and investors.

Through the accelerator, we successfully raised funds from five angel investors, enabling us to undertake essential mouse trials that are pivotal for our product development. Additionally, we were thrilled to be accepted into the prestigious Cancer Tech Conference at Roche and the Pioneer Group AI Programme, both of which are testaments to the calibre of support and mentorship we received during the programme.

We cannot recommend the King’s College Spinout Accelerator highly enough. For anyone looking to navigate the challenging waters of biotech innovation, this programme provides not only the resources but also the community and guidance needed to succeed.”

Academic lead: Dr Julien Bergeron, Faculty of Life Sciences & Medicine.

***

The King’s Spinout Accelerator is a 12-month programme dedicated to supporting the translation of inventions, born from ground-breaking research across King’s. Open to all academics and researchers, the programme gives participants access to expert-led masterclasses, 1:1 coaching, dedicated support from an in-house IP & Licensing Manager, and access to King’s Investor Network.

The accelerator is part of a package of support at King’s that aims to build a new pipeline for research commercialisation, to better optimise impact and support innovation.

To find out more about research commercialisation at King’s visit: